Preclinical
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv® platform in the field of corneal eye diseases.
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
Ben Zeskind, chief executive officer of Immuneering, spoke with BioSpace following the annual J.P. Morgan Healthcare conference in San Francisco.
What’s New at the J.P. Morgan Life Healthcare Conference?
With a new year underway, the U.S. Food and Drug Administration is doing some house-cleaning of sorts.
MR Solutions is continuing to expand its support network as its base of preclinical liquid helium free multimodality MRI systems become the norm in research laboratories across the world.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
TARA Biosystems, Inc. reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, showing that TARA’s human iPSC-derived organ-on-a-chip technology can directly measure in vivo cardiac performance.
MorphoSys AG announced presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida.
PRESS RELEASES